Trial
NCT06328036
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Recurrent Glioblastoma, IDH-Wildtype
Intervention
Atezolizumab
Why stopped
Other - Protocol moved to Disapproved
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-30